Navigation Links
Delcath Highlights Phase III Trial Results Presented at ASCO
Date:6/5/2010

turation via PHP has potential life-extending benefits as a treatment for patients suffering with terminal, metastatic disease in the liver.  Our rolling submission to the FDA is underway, and we are extremely excited by the future of this promising new treatment."

The data presented by Dr. Pingpank on June 5th are the result of the trial's Principal Investigator analysis and differ from results of the independent, blinded core lab analysis announced by Delcath on April 21, 2010.  

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.  

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
2. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
3. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Delcath Systems Granted Third Orphan Drug Designation
7. Delcath Enters Agreement to Sell 869,565 Units
8. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
9. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
10. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... periods ended September 30, 2014.  Biorem,s complete 2014 third quarter financial ... Financial Summary:Three-months ended September 30, , Nine-months ... data) , 2014 , 2013 , ... , 5,281 , 6,715 , 14,476 ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... 17, 2014 pH measurement and control ... the pharmaceutical, chemical, and food and beverage industries. But ... and how do pH sensors work? METTLER TOLEDO has ... in process industries with these questions and more. , ... in the process industries. The actual sensor, the pH ...
(Date:11/18/2014)... 18, 2014 Alanda Software, a ... Reporting solutions, announced today that a top tier ... Consummate Provider™ solution in both the U.S. and ... SaaS based, Data Quality remediation portal, designed to ... party Providers improve their ability to capture, transmit ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... -- China-Biotics,Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," "the ... research, development,marketing and distribution of probiotics products, today ... plant at Qing Pu, Shanghai., "The new ... the cornerstone of our,growth strategy. We have put ...
... drive solid ... earnings growth., ST. DAVID,S, Bermuda, May ... for the quarter ended,March 31, 2008. Revenue in the quarter ended March ... quarter. The primary,drivers of the increase in revenue were the net sales ...
... ... AI programs - ... TSX symbol: SBS, CALGARY, May 9 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), ... announced its,2008 first quarter operational and financial results., Highlights, - ...
Cached Biology Technology:China-Biotics, Inc. Completes Foundation for Its New Plant 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 3Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 4Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 5Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 6Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 7Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 8Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 9Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 10Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 11Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 12Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 13Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 14Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 15Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 16Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 17SemBioSys announces first quarter 2008 financial and operational results 2SemBioSys announces first quarter 2008 financial and operational results 3SemBioSys announces first quarter 2008 financial and operational results 4SemBioSys announces first quarter 2008 financial and operational results 5SemBioSys announces first quarter 2008 financial and operational results 6SemBioSys announces first quarter 2008 financial and operational results 7SemBioSys announces first quarter 2008 financial and operational results 8SemBioSys announces first quarter 2008 financial and operational results 9SemBioSys announces first quarter 2008 financial and operational results 10SemBioSys announces first quarter 2008 financial and operational results 11SemBioSys announces first quarter 2008 financial and operational results 12
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... ORLEANS, LA (2 November 2014)—In support of a bold ... Bill & Melinda Gates Foundation today announced an award ... Malaria Vaccine Initiative (MVI) in building new vaccines that ... help realize the "accelerating to zero" agenda. Such vaccines ... what could be called an "immunological bed net." ...
(Date:11/2/2014)... bar and bump into a biologist . . . , ... nerd sketch, researchers have taken this premise and applied it ... meaning in the rising oceans of genomic data. , In ... genome-wide studies are publishing at a dizzying rate. The challenge ... from the noise (and there is no shortage of noise). ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... spit out the bad. A new study from the Monell ... gatekeeper. The research shows that strong bitter taste in and ... of nausea and display a pattern of stomach activity characteristic ... of quality of life for many people, including pregnant women, ...
... booms, the science of making music, the impact of noise ... just some of the intriguing topics that will be presented ... (ASA). The meeting will take place May 23-27, ... The ASA offers complimentary press registration to bona fide working ...
... you don,t swallow it at allis enough to cause that ... according to a new study reported in the April 12th ... work shows that our body and our physiology anticipate the ... contain toxins or anti-nutrients," said Paul Breslin of the Monell ...
Cached Biology News:The nauseating taste of bitter 2The science of sound 2The science of sound 3The science of sound 4The science of sound 5The science of sound 6Bitterness induces nausea, swallowing not required 2
...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Donor Goat Serum...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: